Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Enregistré dans:
Auteurs principaux: | Berkay Ekici, Mehmet Yaman, Murathan Küçük, Seçkin Dereli, Mustafa Yenerçağ, Zerrin Yiğit, Mehmet Memduh Baş, Yusuf Karavelioğlu, Hüseyin Altuğ Çakmak, Tarık Kıvrak, Hakan Özkan, Cihan Altın, Cengiz Şabanoğlu, Burcu Demirkan, Ali Ekber Ataş, Fethi Kılıçaslan, Hakan Altay, İstemihan Tengiz, Aycan Fahri Erkan, Barış Kılıçaslan, Fatih Erkam Olgun, Murtaza Emre Durakoğlugil, Aslıhan Alhan, Mehdi Zoghi |
---|---|
Format: | article |
Langue: | EN TR |
Publié: |
KARE Publishing
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5aa0136efcca4d2285e92d2abb9da18c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
par: Pankaj Jariwala, et autres
Publié: (2021) -
ARNI, LBBB, COVID-19 and various other topics
par: Çetin Erol
Publié: (2021) -
Neprilysin as a Biomarker: Challenges and Opportunities
par: Noemi Pavo, et autres
Publié: (2020) -
Relevance of Neutrophil Neprilysin in Heart Failure
par: Suriya Prausmüller, et autres
Publié: (2021) -
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
par: Ferhat Dindaş, et autres
Publié: (2021)